{
    "nctId": "NCT00083174",
    "briefTitle": "Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer",
    "officialTitle": "A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 4560,
    "primaryOutcomeMeasure": "Percentage of Women With Serious Adverse Events",
    "eligibilityCriteria": "* At increased risk of developing breast cancer, due to at least one of the following risk factors:\n\n  * Gail score \u2265 1.66\n  * Age \u2265 60 years\n  * Prior atypical ductal hyperplasia, lobular hyperplasia, or lobular carcinoma in situ on breast biopsy\n  * Prior ductal carcinoma in situ (DCIS) treated with total mastectomy with or without tamoxifen (tamoxifen must have been completed \u2265 3 months prior to randomization)\n* No prior DCIS treated with lumpectomy with or without radiation\n* No prior invasive breast cancer\n* Not BRCA1 or BRCA2 carriers\n\nPATIENT CHARACTERISTICS:\n\nPrevious:\n\n* 35 and over\n* Female\n* Postmenopausal, defined as one of the following:\n\n  * over 50 years of age with no spontaneous menses for at least 12 months before study entry\n  * 50 years of age or under with no menses (spontaneous or secondary to hysterectomy) for at least 12 months before study entry AND with follicle-stimulating hormone level within postmenopausal range\n  * Underwent prior bilateral oophorectomy\n* No other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumors with no evidence of disease for \u2265 5 years\n* No uncontrolled hypothyroidism or hyperthyroidism\n* No major medical or psychiatric illness (including substance and alcohol abuse within the past 2 years) that would preclude study participation or compliance\n* Must be accessible for treatment and follow-up\n* Willing to complete quality of life questionnaires in either English or French\n\nCurrent: MAP.3 participants who were randomized to the exemestane arm, are currently receiving exemestane as part of the MAP.3 study and who have not completed 5 years of exemestane.\n\nOR MAP.3 study participants who were randomized to the placebo arm and who have either completed 5 years of study drug or who are still receiving placebo. Note: this applies only to centres that choose to allow placebo \"cross-over\".\n\nPRIOR CONCURRENT THERAPY:\n\nPrevious:\n\n* More than 3 months since prior and no concurrent hormone replacement therapies\n* More than 3 months since systemic estrogenic, androgenic, or progestational agents\n* More than 3 months since prior and no concurrent hormonal therapies, including, but not limited to the following:\n\n  * Luteinizing-hormone releasing-hormone analogs (e.g., goserelin or leuprolide)\n  * Progestogens (e.g., megestrol)\n  * Prolactin inhibitors (e.g., bromocriptine)\n  * Antiandrogens (e.g., cyproterone acetate)\n  * Selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene)\n* No investigational drug within 30 days or 5 half lives prior to randomization\n* No concurrent endocrine therapy\n* No concurrent estrogens, androgens, or progesterones\n* Concurrent low dose (\u2264 100 mg/day) prophylactic aspirin allowed\n* Concurrent bisphosphonates for prevention or treatment of osteoporosis allowed\n* No other concurrent medications that may have an effect on study endpoints\n\nCurrent: There are no prior concurrent therapy restrictions for the amended MAP.3 study.",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}